- Fellowship - National Institutes of Health (1969-1973), Biochemical Genetics
- Residency - Massachusetts General Hospital (1968-1969), Medicine
- Internship - Massachusetts General Hospital (1967-1968), Medicine
- Medical School - Stanford University Medical Center (1963-1967)
John Minna, M.D.
- Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology
- Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
- Internal Medicine - Hematology/Oncology
- Lung Cancer
Stanford University, Stanford, CA A.B. 1963 Psychology Stanford Medical School, Stanford, CA M.D. 1967 Medicine Massachusetts General Hospital, Boston, MA 1967-1969 Internal Medicine National Institutes of Health, Bethesda, MD 1969-1973 Genetics A. Positions and Honors. 1963-1967 Predoctoral Trainee PHS, Dept of Genetics, Stanford Medical School (Dr. L. Herzenberg) 1967-1969 Internship and Residency, Dept of Medicine, Massachusetts General Hosp, Boston, MA 1969-1973 Res Assoc, Lab. of Biochemical Genetics (LBG), NHLBI, NIH (Dr. Marshall Nirenberg) 1973-1975 Head, Section on Somatic Cell Genetics, LBG, NHLBI, NIH 1974-1991 Attending Physician, Clinical Center, NIH 1975-1981 Chief, NCI-VA Medical Oncology Branch, Clinical Oncology Program, DCT, NCI, NIH 1981-1991 Chief, NCI-Navy Medical Oncology Branch, COP, DCT, NCI, NIH 1981-1991 Prof of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 1969-1991 United States Public Health Service (PHS); Captain (06); Retired 1991 1991-Pres. Prof of Medicine & Pharmacology, UT Southwestern Medical Center Dallas (UTSWMC) 1991-1995 Director, Harold C. Simmons Cancer Center, UTSWMC, Lisa K. Simmon Distinguished Chair in Comprehensive Oncology, Chief, Division of Medical Oncology/Hematology 1995-Pres. Director, Hamon Center for Therapeutic Oncology Research and W.A. "Tex" & Deborah Moncrief Jr. Center for Cancer Genetics, UTSWMC, Sarah M. & Charles E. Seay Distinguished Chair in Cancer Research, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology Honors PHS: Commendation Medal (1979), Meritorious Service Medical (1986), Unit Commendation Medal (1991); Rosenthal Prize for Cancer Research (1984); Milken Foundation Award for Scientific Excellence in Clinical Research (1989); Chester Stock Award, Memorial Sloan-Kettering Cancer Center (1992); Bristol Myers Squibb Award for Lung Cancer Research (1997); Moran Award Univ. Michigan (2000), NCI SPORE Program Award for Leadership (2003), Ochsner Award Smoking Related Research (2004), ASCO Scientific Achievement Award (2005), ASCO Lifetime Achievement Award (2007) B. Selected peer-reviewed publications (2006-2007). Sato, M., Vaughan, M. B., Girard, L., Peyton, M., Lee, W., Shames, D. S., Ramirez, R. D., Sunaga, N., Gazdar, A. F., Shay, J. W., and Minna, J. D. Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells. Cancer Res, 66: 2116-2128, 2006. Zhou, B. B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., Yang, G., Li, Y., Yao, W., Vaddi, K., Gazdar, A. F., Friedman, S. M., Jablons, D. M., Newton, R. C., Fridman, J. S., Minna, J. D., and Scherle, P. A. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell, 10: 39-50, 2006. Deng, W. G., Kawashima, H., Wu, G., Jayachandran, G., Xu, K., Minna, J. D., Roth, J. A., and Ji, L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res, 67: 709-717, 2007. Lam, D. C., Girard, L., Ramirez, R., Chau, W. S., Suen, W. S., Sheridan, S., Tin, V. P., Chung, L. P., Wong, M. P., Shay, J. W., Gazdar, A. F., Lam, W. K., and Minna, J. D. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res, 67: 4638-4647, 2007. Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., Xie, X. J., and White, M. A. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature, 446: 815-819, 2007.
- Fellow American College of Physicians (FACP)
- Association of American Physicians (AAP)
- ASBMB, ASCI, AFCR, ASH, IASLC
- American Society of Clinical Oncology (ASCO)
- American Association for Cancer Research (AACR)
- Rosenthal Prize 1984, Prize for Cancer Research
- Bristol Myers Squibb Award 1997, Award for Lung Cancer Research
- Ochsner Award 2004, Award for Smoking Related Research
- ASCO Award 2005, Lifetime Scientific Achievement
Targeted therapies for lung cancer: clinical experience and novel agents.
Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD Cancer journal (Sudbury, Mass.) 2011 Nov-Dec 17 6 512-27
Cancer stem cells.
Rudin C, Minna J Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Nov 4 11 Suppl 3 S1079-81
Small-cell lung cancer: translational research enroute to therapeutic advances.
Dowell J, Minna JD Oncology (Williston Park, N.Y.) 2008 Nov 22 13 1493, 1495
Tumor oncogenotypes and lung cancer stem cell identity.
Sullivan JP, Minna JD Cell stem cell 2010 Jul 7 1 2-4
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD Proceedings of the National Academy of Sciences of the United States of America 2014 Sep
Radiation-Enhanced Lung Cancer Progression in a Transgenic Mouse Model of Lung Cancer Is Predictive of Outcomes in Human Lung and Breast Cancer.
Delgado O, Batten KG, Richardson JA, Xie XJ, Gazdar AF, Kaisani AA, Girard L, Behrens C, Suraokar M, Fasciani G, Wright WE, Story MD, Wistuba II, Minna JD, Shay JW Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Feb
Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach.
Mayba O, Gnad F, Peyton M, Zhang F, Walter K, Du P, Huntley MA, Jiang Z, Liu J, Haverty PM, Gentleman RC, Li R, Minna JD, Li Y, Shames DS, Zhang Z Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2014 75-86
A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer Patients.
Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, Mao JH, White M, Wistuba II, Minna JD, Xie Y Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jan
TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival.
Yoshida K, Sato M, Hase T, Elshazley M, Yamashita R, Usami N, Taniguchi T, Yokoi K, Nakamura S, Kondo M, Girard L, Minna JD, Hasegawa Y Cancer science 2013 Feb 104 2 171-7
Precision Medicine for Cancer Patients: Lessons Learned and the Path Forward.
Gazdar AF, Minna JD Journal of the National Cancer Institute 2013 Aug
Pre-Clinical Studies of Epigenetic Therapies Targeting Histone Modifiers in Lung Cancer.
Huffman K, Martinez ED Frontiers in oncology 2013 3 235
Systems approaches to modeling chronic mucosal inflammation.
Kalita M, Tian B, Gao B, Choudhary S, Wood TG, Carmical JR, Boldogh I, Mitra S, Minna JD, Brasier AR BioMed research international 2013 2013 505864
The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD, Roth JA PloS one 2013 8 10 e77067
Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome.
Story M, Ding LH, Brock WA, Ang KK, Alsbeih G, Minna J, Park S, Das A Health physics 2012 Nov 103 5 596-606
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y Annals of surgical oncology 2012 Jul 19 Suppl 3 S634-45
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, Ishiguro F, Osada H, Sekido Y, Yokoi K, Usami N, Shames DS, Kondo M, Gazdar AF, Minna JD, Hasegawa Y International journal of cancer. Journal international du cancer 2012 Dec 131 12 2820-31
Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.
Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD, Mangelsdorf DJ Molecular endocrinology (Baltimore, Md.) 2012 Aug 26 8 1443-54
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, English J, Murray N, Tsao MS, Minna JD, Gazdar AF, Wistuba II, MacAulay CE, Lam S, Lam WL PloS one 2012 7 5 e37775
How do we safely get people to stop smoking?
Lam DC, Minna JD Cancer prevention research (Philadelphia, Pa.) 2011 Nov 4 11 1724-7
From mice and men to earth and space: joint NASA-NCI workshop on lung cancer risk resulting from space and terrestrial radiation.
Shay JW, Cucinotta FA, Sulzman FM, Coleman CN, Minna JD Cancer research 2011 Nov 71 22 6926-9
Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy.
Xie Y, Minna JD Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Oct 28 29 4404-7
Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy.
Sullivan JP, Minna JD, Shay JW Cancer metastasis reviews 2010 Mar 29 1 61-72
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?
Gazdar AF, Gao B, Minna JD Lung cancer (Amsterdam, Netherlands) 2010 Jun 68 3 309-18
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD Cancer research 2010 Aug 70 16 6477-85
MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachment.
Spinola M, Falvella FS, Colombo F, Sullivan JP, Shames DS, Girard L, Spessotto P, Minna JD, Dragani TA Molecular cancer 2010 9 62
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M PloS one 2012 7 6 e36116
EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance.
Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G, Levine B Cell 2013 Sep 154 6 1269-84
Molecular biology of lung cancer.
Cooper WA, Lam DC, O'Toole SA, Minna JD Journal of thoracic disease 2013 Oct 5 Suppl 5 S479-S490
Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.
Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P Cancer research 2013 May
MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients.
Pu X, Roth JA, Hildebrandt MA, Ye Y, Wei H, Minna JD, Lippman SM, Wu X Cancer research 2013 Feb
NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM.
Osborne JK, Larsen JE, Shields MD, Gonzales JX, Shames DS, Sato M, Kulkarni A, Wistuba II, Girard L, Minna JD, Cobb MH Proceedings of the National Academy of Sciences of the United States of America 2013 Apr 110 16 6524-9
Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M Oncogene 2012 Sep
Probe mapping across multiple microarray platforms.
Allen JD, Wang S, Chen M, Girard L, Minna JD, Xie Y, Xiao G Briefings in bioinformatics 2012 Sep 13 5 547-54
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.
Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, Minna J, Roth JA, Swisher SG, Fang B Biochemical pharmacology 2012 May 83 10 1456-64
Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M International journal of cancer. Journal international du cancer 2011 May
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD Molecular cancer therapeutics 2011 Feb 10 2 336-46
Lung cancer cell lines as tools for biomedical discovery and research.
Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD Journal of the National Cancer Institute 2010 Sep 102 17 1310-21
Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.
Gazdar AF, Minna JD Cancer prevention research (Philadelphia, Pa.) 2008 Aug 1 3 156-60
Comparison between concurrent and sequential chemoradiation for non-small cell lung cancer in vitro.
Song SY, DAS AK, Minna JD Oncology letters 2014 Feb 7 2 307-310
Distinct transcriptome profiles identified in normal human bronchial epithelial cells after exposure to ?-rays and different elemental particles of high Z and energy.
Ding LH, Park S, Peyton M, Girard L, Xie Y, Minna JD, Story MD BMC genomics 2013 14 372
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G Journal of the National Cancer Institute 2012 Feb 104 3 228-39
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.
Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD Cancer research 2010 Dec 70 23 9937-48
A lung cancer molecular prognostic test ready for prime time.
Xie Y, Minna JD Lancet 2012 Mar 379 9818 785-7
GWAS Meets TCGA to Illuminate Mechanisms of Cancer Predisposition.
Kim HS, Minna JD, White MA Cell 2013 Jan 152 3 387-9
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM Molecular cancer therapeutics 2012 Sep 11 9 2021-32
Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients.
Xie Y, Xiao G, Coombes K, Behrens C, Solis LM, Raso MG, Girard L, Erickson HS, Roth JA, Heymach JV, Moran C, Danenberg KD, Minna JD, Wistuba II Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jul 5705-14
Essential role of aldehyde dehydrogenase 1A3 (ALDH1A3) for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.
Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez J, Liu H, Behrens C, Shay JW, Wistuba II, Minna JD Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Jun
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Sep
miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer.
Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A Oncogene 2013 Sep
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.
Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA Cell 2013 Oct 155 3 552-66
Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells.
Zaganjor E, Osborne JK, Weil LM, Diaz-Martinez LA, Gonzales JX, Singel SM, Larsen JE, Girard L, Minna JD, Cobb MH Oncogene 2013 Nov
Pathway-based serum microRNA profiling and survival in patients with advanced non-small cell lung cancer.
Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman SM, Ye Y, Minna JD, Wu X Cancer research 2013 Jun
KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.
Dai B, Yoo SY, Bartholomeusz G, Graham RA, Majidi M, Yan S, Meng J, Ji L, Coombes K, Minna JD, Fang B, Roth JA Cancer research 2013 Jul
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jan 19 1 279-90
Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention.
Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR Cancer prevention research (Philadelphia, Pa.) 2013 Feb 6 2 100-8
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, Dimaio JM, Gao B, Xie Y, Wistuba II, Gazdar AF, Shay JW, Minna JD Molecular cancer research : MCR 2013 Feb
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Lu H, Wang L, Gao W, Meng J, Dai B, Wu S, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B Molecular cancer therapeutics 2013 Dec 12 12 2864-73
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV Cancer discovery 2012 Sep 2 9 798-811
NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition.
Osborne JK, Larsen JE, Gonzales JX, Shames DS, Sato M, Wistuba II, Girard L, Minna JD, Cobb MH Oncogenesis 2013 2 e63
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.
Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S Nature genetics 2012 Oct 44 10 1111-6
Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study.
Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Nov 18 21 5983-91
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.
Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, Chan J, Holcomb T, Dijkgraaf P, Johnson S, Koeman J, Minna JD, Gazdar AF, Stern HM, Hoeflich KP, Wu TD, Settleman J, de Sauvage FJ, Gentleman RC, Neve RM, Stokoe D, Modrusan Z, Seshagiri S, Shames DS, Zhang Z Genome research 2012 Dec 22 12 2315-27
miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, Pertsemlidis A PloS one 2012 7 6 e39167
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-a-independent manner.
Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, Harran P, Wang L, Brekken RA, Wang X, Minna JD Cancer research 2011 Dec 71 24 7640-8
Molecular biology of lung cancer: clinical implications.
Larsen JE, Minna JD Clinics in chest medicine 2011 Dec 32 4 703-40
Radiogenomics predicting tumor responses to radiotherapy in lung cancer.
Das AK, Bell MH, Nirodi CS, Story MD, Minna JD Seminars in radiation oncology 2010 Jul 20 3 149-55
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
Gerber DE, Minna JD Cancer cell 2010 Dec 18 6 548-51
Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer.
Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, Minna JD, Mangelsdorf DJ PLoS medicine 2010 7 12 e1000378
Multifocal lung cancers--clonality vs field cancerization and does it matter?
Gazdar AF, Minna JD Journal of the National Cancer Institute 2009 Apr 101 8 541-3
ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.
Agirre X, Román-Gómez J, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, Vázquez I, Zalacain M, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F Oncogene 2006 Mar 25 13 1862-70
- Targeted therapies for lung cancer: clinical experience and novel agents.
- Molecular pathogenesis of human cancer
- Molecular biomarkers of response to cancer therapy
- Lung Cancer
- Genome wide mRNA, protein, and DNA analysis
- Breast Cancer
- Lung Cancer